Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

TCTMD’s Top 10 Most Popular Stories for December 2017

News Daily News

TCTMD’s Top 10 Most Popular Stories for December 2017

December 28, 2017

Attacking DVT With Drug-Device Combo Does Not Reduce Postthrombotic Syndrome

News Daily News

Attacking DVT With Drug-Device Combo Does Not Reduce Postthrombotic Syndrome

December 08, 2017

Data on IVC Filters Sparse but Somewhat Reassuring: Meta-Analysis

News Daily News

Data on IVC Filters Sparse but Somewhat Reassuring: Meta-Analysis

September 19, 2017

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

News Features

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

September 15, 2017

Apixaban May Be Better Choice Than Rivaroxaban for DVT Patients

News Conference News VIVA 2017

Apixaban May Be Better Choice Than Rivaroxaban for DVT Patients

September 11, 2017

News Daily News

Betrixaban Approved for Prevention of VTE

Michael O'Riordan

June 23, 2017

Inferior Vena Cava Filters: The Longer They’re In, the Higher the Risk of Adverse Events

News Daily News

Inferior Vena Cava Filters: The Longer They’re In, the Higher the Risk of Adverse Events

June 19, 2017

News Daily News

Apixaban Recalled Following Complaints of Dose-Packaging Mismatch

June 13, 2017

Registry Study Makes Case Against Vena Cava Filter Use in Trauma Patients, but Experts Say Not So Fast

News Daily News

Registry Study Makes Case Against Vena Cava Filter Use in Trauma Patients, but Experts Say Not So Fast

Yael L. Maxwell

May 10, 2017

Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE

News Conference News ACC 2017

Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE

March 18, 2017

Percutaneous Bypass for Long, Complex SFA Lesions Holds Up Well to 6 Months: DETOUR I Study

News Conference News ISET 2017

Percutaneous Bypass for Long, Complex SFA Lesions Holds Up Well to 6 Months: DETOUR I Study

February 10, 2017

Rivaroxaban’s “Overwhelming” Efficacy for Coronary, Peripheral Disease Leads to Early Halt of COMPASS

News Daily News

Rivaroxaban’s ‘Overwhelming’ Efficacy for Coronary, Peripheral Disease Leads to Early Halt of COMPASS

February 08, 2017

Who Should Undergo Deep Vein thrombosis Lysis? A Review of The Trial Data

Presentation ISET 2017

Who Should Undergo Deep Vein thrombosis Lysis? A Review of The Trial Data

Presenter: William T. Kuo

February 04, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.